News
What Makes Moog (MOG.A) a New Buy Stock
Moog (MOG.A) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock
M/A-Com (MTSI) is a Great Momentum Stock: Should You Buy?
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
What Makes Biorestorative Therapies (BRTX) a New Buy Stock
Biorestorative Therapies, Inc. (BRTX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces
Vishay Precision (VPG) Is Up 11.66% in One Week: What You Should Know
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even
Credit Acceptance (CACC) Upgraded to Buy: What Does It Mean for the Stock?
Credit Acceptance (CACC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one
Strength in ROP's Application Software Unit Seems Firm: More Upside Ahead?
Roper Technologies, Inc. ROP continues to benefit from strength in its Application Software segment. Strong momentum across its Aderant, Deltek, Vertafore, PowerPlan and CentralReach businesses is
Is THG Expanding Its Motorcycle & ORV Insurance Offerings?
The Hanover Insurance Group THG is expanding its motorcycle and off-road vehicle (ORV) insurance offerings across multiple U.S. states as part of its broader strategy to strengthen its total account
Hack-Proof Your Portfolio: The Bull Case for Cybersecurity ETFs
As AI adoption accelerates and Big Tech ramps up spending on AI infrastructure, demand for cybersecurity solutions is expected to rise alongside it. Greater AI integration increases the need for
BABA Q4 Profit Falls on Heavy Tech Spending: Time to Sell the Stock?
Alibaba Group BABA closed its fiscal 2026 with a sobering message for investors — the cost of staying relevant in the artificial intelligence (AI) era is steep, and shareholders are footing the
Will Stillwater Facility Ramp-Up Drive Long-Term Growth for USAR?
USA Rare Earth, Inc. USAR has achieved a key milestone with the commissioning of Phase 1a of its commercial magnet production line at the Stillwater facility in Oklahoma. The development enables
Here's Why Investors Should Stay Neutral on CNO Financial for Now
CNO Financial Group, Inc. CNO is strategically positioned for growth, supported by strong collected premiums from life and health products, rising new annualized premiums and higher fee revenues. A
Analog Devices Climbs 57% YTD: Time to Buy, Sell or Hold the Stock?
Analog Devices ADI shares have jumped 57.3% year to date, underperforming the Zacks Semiconductor - Analog and Mixed industry and the Zacks Computer and Technology sector’s appreciation of 67.4% and
Here's Why You Should Add Pediatrix Medical to Your Portfolio Now
Pediatrix Medical Group, Inc. MD is well-poised for growth, benefiting from stronger cash collections, a favorable payer mix and higher patient acuity in neonatology. Strategic acquisitions are
Applied Materials Q2 Earnings Beat Estimates, Revenues Increase Y/Y
Applied Materials AMAT reported second-quarter fiscal 2026 non-GAAP earnings of $2.86 per share, which beat the Zacks Consensus Estimate by 6.5%. AMAT’s second-quarter fiscal 2026 non-GAAP earnings
Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?
Corcept Therapeutics’ CORT sole marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing’s syndrome, has been witnessing steady demand. Currently, the company’s top line
Argan's EBITDA Margin Rises to 21.4%: Is Execution Becoming a Moat?
Argan, Inc.’s AGX fourth-quarter performance suggests that execution is becoming more than just an operating strength — it may be turning into a competitive moat. The company’s EBITDA rose to $56
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANI Pharmaceuticals’ ANIP business is moving deeper into specialty, with Rare Disease and Brands now positioned as the primary growth driver. The first quarter of 2026 reinforced that tilt, with
Are You Looking for a High-Growth Dividend Stock?
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent
Tompkins Financial (TMP) Could Be a Great Choice
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent
Fulton Financial (FULT) Could Be a Great Choice
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from
Ameren (AEE) Could Be a Great Choice
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from
Why Fifth Third Bancorp (FITB) is a Great Dividend Stock Right Now
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But for income investors, generating consistent cash flow from
Why Phillips Edison & Company, Inc. (PECO) is a Top Dividend Stock for Your Portfolio
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. However, when you're an income investor, your primary focus is
First United Corporation (FUNC) Could Be a Great Choice
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your
Datavalut Gains Traction: 5 Reasons to Sell Now
Datavault (NASDAQ: DVLT) is gaining traction and is on track to begin ramping its revenue. However, a combination of factors suggests a revenue ramp won't be enough to make a difference for this


